Li Sun
Research Subjects
Li Sun has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Eric J. Woolf
Pharmacokinetics, Pharmacodynamics, & Drug Metabolism (PPDM), MRL, Merck & Co., Inc., Kenilworth, NJ, United States
2 shared publicationsJulie A. Stenken
2 shared publications- Sheila Breidinger
Merck Research Labs—PPDM Clinical Bioanalytics
2 shared publications Amy Y. Yang
1 shared publicationBob Thornton
Translational Pharmacology, MRL, Merck & Co., Inc., Kenilworth, NJ, United States
1 shared publicationDonald G. Musson
1 shared publication
Latest Publications
- 2 October 2012
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 84 (20) , 8614-8621
Ultrasensitive Liquid Chromatography–Tandem Mass Spectrometric Methodologies for Quantification of Five HIV-1 Integrase Inhibitors in Plasma for a Microdose Clinical Trial
HIV-1 integrase strand transfer inhibitors are an important class of compounds targeted for the treatment of HIV-1 infection. Microdosing has emerged as an attractive tool to assist in drug candidate screening for clinical development, but necessitates extremely sensitive bioanalytical assays, typically in the pg/mL concentration range. Currently, accelerator mass spectrometry is the predominant tool for microdosing support, which requires a specialized facility and synthesis of radiolabeled compounds. There have been few studies attempted to comprehensively assess a liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach in the context of microdosing applications. Herein, we describe the development of automated LC-MS/MS methods to quantify five integrase inhibitors in plasma with the limits of quantification at 1 pg/mL for raltegravir and 2 pg/mL for four proprietary compounds. The assays involved double extractions followed by UPLC coupled with negative ion electrospray MS/MS analysis. All methods were fully validated to the rigor of regulated bioanalysis requirements, with intraday precision between 1.20 and 14.1% and accuracy between 93.8 and 107% at the standard curve concentration range. These methods were successfully applied to a human microdose study and demonstrated to be accurate, reproducible, and cost-effective. Results of the study indicate that raltegravir displayed linear pharmacokinetics between a microdose and a pharmacologically active dose.
- 2 October 2012
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 84 (20) , 8614-8621
Ultrasensitive Liquid Chromatography–Tandem Mass Spectrometric Methodologies for Quantification of Five HIV-1 Integrase Inhibitors in Plasma for a Microdose Clinical Trial
HIV-1 integrase strand transfer inhibitors are an important class of compounds targeted for the treatment of HIV-1 infection. Microdosing has emerged as an attractive tool to assist in drug candidate screening for clinical development, but necessitates extremely sensitive bioanalytical assays, typically in the pg/mL concentration range. Currently, accelerator mass spectrometry is the predominant tool for microdosing support, which requires a specialized facility and synthesis of radiolabeled compounds. There have been few studies attempted to comprehensively assess a liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach in the context of microdosing applications. Herein, we describe the development of automated LC-MS/MS methods to quantify five integrase inhibitors in plasma with the limits of quantification at 1 pg/mL for raltegravir and 2 pg/mL for four proprietary compounds. The assays involved double extractions followed by UPLC coupled with negative ion electrospray MS/MS analysis. All methods were fully validated to the rigor of regulated bioanalysis requirements, with intraday precision between 1.20 and 14.1% and accuracy between 93.8 and 107% at the standard curve concentration range. These methods were successfully applied to a human microdose study and demonstrated to be accurate, reproducible, and cost-effective. Results of the study indicate that raltegravir displayed linear pharmacokinetics between a microdose and a pharmacologically active dose.
- 15 February 2012
- Published by Elsevier in Journal of Chromatography B
- Vol. 885-886, 15-23
Quantitative determination of odanacatib in human plasma using liquid–liquid extraction followed by liquid chromatography–tandem mass spectrometry analysis
- 15 February 2012
- Published by Elsevier in Journal of Chromatography B
- Vol. 885-886, 15-23
Quantitative determination of odanacatib in human plasma using liquid–liquid extraction followed by liquid chromatography–tandem mass spectrometry analysis
- 1 November 2007
- Published by Elsevier in Analytical Biochemistry
- Vol. 370 (1) , 26-37
An in vitro microdialysis methodology to study 11β-hydroxysteroid dehydrogenase type 1 enzyme activity in liver microsomes
- 1 November 2007
- Published by Elsevier in Analytical Biochemistry
- Vol. 370 (1) , 26-37
An in vitro microdialysis methodology to study 11β-hydroxysteroid dehydrogenase type 1 enzyme activity in liver microsomes
- 1 August 2007
- Published by Elsevier in Journal of Chromatography A
- Vol. 1161 (1-2) , 261-268
The effect of β-cyclodextrin on liquid chromatography/electrospray-mass spectrometry analysis of hydrophobic drug molecules
- 1 August 2007
- Published by Elsevier in Journal of Chromatography A
- Vol. 1161 (1-2) , 261-268
The effect of β-cyclodextrin on liquid chromatography/electrospray-mass spectrometry analysis of hydrophobic drug molecules